AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.150

-0.020-0.92%

Volume:1.50M

Turnover:3.21M

Market Cap:2.79B

PE:-34.72

High:2.175

Open:2.160

Low:2.130

Close:2.170

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:0.69

T/O Rate:0.19%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.062

EPS(LYR):-0.062

ROE:-9.86%

ROA:-4.11%

PB:3.52

PE(LYR):-34.72

Loading ...

Overview Company News Filings

Mesoblast to host inaugural R&D Day webcast

Mesoblast Director George Gregory Files Initial Beneficial Ownership Statement

Is Mesoblast's New Clinical Leader Quietly Reframing Its Commercialization Story for Cell Therapies (ASX:MSB)?

Simply Wall St.

A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans

Simply Wall St.

Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs

DR. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

THOMSON REUTERS

Mesoblast Ltd-Appointment of Clinical Development and Medical Affairs Head

THOMSON REUTERS

Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/MSB.AU/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.15,"timestamp":1789107120000,"preClose":2.17,"halted":0,"volume":1495321,"delay":0,"changeRate":-0.00921658986175116,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.061924686192468624,"marketStatus":"Market Closed","change":-0.02,"latestTime":"09-11 16:12:00 AEST","open":2.16,"high":2.175,"low":2.13,"amount":3214747,"amplitude":0.020737,"askPrice":2.18,"askSize":2781,"bidPrice":2.14,"bidSize":7068,"shortable":3,"etf":0,"ttmEps":-0.061924686192468624,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789344000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.17,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":0.6924478904739069,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.17,"auctionPrice":2.15,"auctionVolume":251472,"auction":3,"marketStatus":"盘后竞价","timestamp":1789107003558}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.061925,"volumeRatio":0.6924478904739069,"shares":1296862776,"dividePrice":0,"high":2.175,"amplitude":0.020737,"preClose":2.17,"low":2.13,"week52Low":1.88,"pbRate":"3.52","psRate":"16.63","week52High":3.31,"institutionHeld":0,"latestPrice":2.15,"committee":0.435273,"eps":-0.061924686192468624,"divideRate":0,"volume":1495321,"delay":0,"ttmEps":-0.061924686192468624,"open":2.16,"prevYearClose":2.72,"prevWeekClose":2.38,"prevMonthClose":2.36,"prevQuarterClose":1.955,"fiveDayClose":2.38,"twentyDayClose":2.21,"sixtyDayClose":2.13,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620401554","title":"Mesoblast to host inaugural R&D Day webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401554","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401554?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:20","pubTimestamp":1773789612,"startTime":"0","endTime":"0","summary":"Mesoblast will host an R&D Day on April 8, 2026 in New York City. The event is scheduled to run from 8:00am to 11:00am EST and will be webcast. The webcast link is .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL6HbfW4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU0314104364.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4585","IE00B64PRP62.GBP","BK7501","LU2210149790.SGD","SG9999014005.SGD","MSB.AU","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BGHQF748.EUR","BK4112","SG9999014013.SGD","BK7067","IE00BN0W2T93.GBP","BK7508","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620497684","title":"Mesoblast Director George Gregory Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497684","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497684?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:07","pubTimestamp":1773698829,"startTime":"0","endTime":"0","summary":"Mesoblast reported an initial statement of beneficial ownership by director George Gregory. The filing listed indirect warrants for 6.83 million ordinary shares with an exercise price of USD 2.86. It also listed direct warrants for 200,000 ADS with an exercise price of USD 9.06. The filing also included direct options covering 66,667 ordinary shares with an exercise price of USD 1.72.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL8ctFfz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7067","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619412639","title":"Is Mesoblast's New Clinical Leader Quietly Reframing Its Commercialization Story for Cell Therapies (ASX:MSB)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619412639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619412639?lang=en_us&edition=fundamental","pubTime":"2026-03-14 15:37","pubTimestamp":1773473852,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast Limited created a new senior leadership role and appointed Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose, to lead medical affairs, clinical collaborations and investigator-initiated trials across its cell therapy programs.\nBy bringing in a physician-scientist with extensive experience in early pipeline studies and investigator-sponsored research at major biopharmaceutical companies,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblasts-new-clinical-leader-quietly-reframing-its-comm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblasts-new-clinical-leader-quietly-reframing-its-comm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","MSB","BK4006","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618130978","title":"A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130978?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:27","pubTimestamp":1773322071,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has drawn fresh attention after appointing Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, a move that coincides with its upcoming Bell Potter Healthcare Horizons Summit presentation.\nSee our latest analysis for Mesoblast.\nThe recent appointment and upcoming summit appearance come after a tougher stretch for the share price, with a 30 day share price return of 14.4% and a 90 day share price return of 22.74%. However, the 3 year total...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblasts-asxmsb-valuation-as-leadership-changes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblasts-asxmsb-valuation-as-leadership-changes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7508","BK7501","BK4006","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618797413","title":"Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618797413","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618797413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271313,"startTime":"0","endTime":"0","summary":"Mesoblast appointed Teresa Montagut as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Eric Rose. Montagut will lead the medical affairs organization and support investigator-initiated trials and clinical collaborations. She joined Mesoblast from Regeneron, where she was Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. Mesoblast said Montagut will support efforts to expand indications for its cell therapy programs in pediatric and adult inflammatory conditions.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbkSytc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","REGN","LU0882574055.USD","LU0320765992.SGD","LU2095319765.USD","LU2210149790.SGD","LU0109394709.USD","LU2362540622.SGD","LU0058720904.USD","LU0823434740.USD","LU2468319806.SGD","LU2023250504.SGD","MSB.AU","LU2089984988.USD","BK7508","LU0889565916.HKD","IE00BKPKM429.USD","LU2106854487.HKD","BK4588","LU0823416689.USD","NDAQ","BK7067","LU2237438978.USD","SG9999014021.USD","LU0114720955.EUR","IE00B64PRP62.GBP","BK4139","LU0053666078.USD","LU1974910355.USD","LU2362541273.HKD","LU2362541513.USD","BK7501","LU1917777945.USD","IE00BGHQF748.EUR","BK4585","IE00B3QW5Z07.USD","LU2210150020.SGD","LU0289739699.SGD","LU0314104364.USD","LU0823434583.USD","SG9999014005.SGD","BK4112","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618974134","title":"DR. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618974134?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271299,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA281YNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618882974","title":"Mesoblast Ltd-Appointment of Clinical Development and Medical Affairs Head","url":"https://stock-news.laohu8.com/highlight/detail?id=2618882974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618882974?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:58","pubTimestamp":1773269921,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUE4PZNBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7067","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617137","title":"Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617137?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:37","pubTimestamp":1773038279,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  acute graft-versus-host disease  drug candidate, CYP-001's potential has been reinforced by Mesoblast's  fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric , generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4007","BK7067","BK7508","BK4139","MESO","MSB.AU","BK7501","CYP.AU","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":188,"code":"91000000","status":"200"}]}}